Abstract
The coronavirus disease 2019 (COVID-19) pandemic has underscored the lack of approved drugs against acute viral diseases. Plants are considered inexhaustible sources of drugs for several diseases and clinical conditions, but plant-derived compounds have seen little success in the field of antivirals. Here, we present the case for the use of compounds from vascular plants, including alkaloids, flavonoids, polyphenols, and tannins, as antivirals, particularly for the treatment of COVID-19. We review current evidence for the use of these phytochemicals against SARS-CoV-2 infection and present their potential targets in the SARS-CoV-2 replication cycle.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Abdallah, H.M., El-Halawany, A.M., Sirwi, A., El-Araby, A.M., Mohamed, G.A., Ibrahim, S.R.M., Koshak, A.E., Asfour, H.Z., Awan, Z.A., and Elfaky, M.A. 2021. Repurposing of some natural product isolates as SARS-COV-2 main protease inhibitors via in vitro cell free and cell-based antiviral assessments and molecular modeling approaches. Pharmaceuticals 14, 213.
Abian, O., Ortega-Alarcon, D., Jimenez-Alesanco, A., Ceballos-Laita, L., Vega, S., Reyburn, H.T., Rizzuti, B., and Velazquez-Campoy, A. 2020. Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening. Int. J. Biol. Macromol. 164, 1693–1703.
Alhadrami, H.A., Sayed, A.M., Sharif, A.M., Azhar, E.I., and Rateb, M.E. 2021. Olive-derived triterpenes suppress SARS COV-2 main protease: a promising scaffold for future therapeutics. Molecules 26, 2654.
Ali, S.I., Sheikh, W.M., Rather, M.A., Venkatesalu, V., Muzamil Bashir, S., and Nabi, S.U. 2021. Medicinal plants: treasure for antiviral drug discovery. Phytother. Res. 35, 3447–3483.
Amalraj, A., Pius, A., Gopi, S., and Gopi, S. 2017. Biological activities of curcuminoids, other biomolecules from turmeric and their derivatives - a review. J. Tradit. Complement. Med. 7, 205–233.
Anand, P., Kunnumakkara, A.B., Newman, R.A., and Aggarwal, B.B. 2007. Bioavailability of curcumin: problems and promises. Mol. Pharm. 4, 807–818.
Armstrong, L.A., Lange, S.M., Dee Cesare, V., Matthews, S.P., Nirujogi, R.S., Cole, I., Hope, A., Cunningham, F., Toth, R., Mukherjee, R., et al. 2021. Biochemical characterization of protease activity of Nsp3 from SARS-CoV-2 and its inhibition by nanobodies. PLoS ONE 16, e0253364.
Atanasov, A.G., Zotchev, S.B., Dirsch, V.M., International Natural Product Sciences Taskforce, and Supuran, C.T. 2021. Natural products in drug discovery: advances and opportunities. Nat. Rev. Drug Discov. 20, 200–216.
Beutler, J.A. 2009. Natural products as a foundation for drug discovery. Curr. Protoc. Pharmacol. 46, 9.11.1–9.11.21.
Cho, J., Lee, Y.J., Kim, J.H., Kim, S.I., Kim, S.S., Choi, B.S., and Choi, J.H. 2020. Antiviral activity of digoxin and ouabain against SARSCoV-2 infection and its implication for COVID-19. Sci. Rep. 10, 16200.
Choy, K.T., Wong, A.Y., Kaewpreedee, P., Sia, S.F., Chen, D., Hui, K.P.Y., Chu, D.K.W., Chan, M.C.W., Cheung, P.P., Huang, X., et al. 2020. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 178, 104786.
Clarke, E.C., Nofchissey, R.A., Ye, C., and Bradfute, S.B. 2021. The iminosugars celgosivir, castanospermine and UV-4 inhibit SARSCoV-2 replication. Glycobiology 31, 378–384.
Clementi, N., Scagnolari, C., D'Amore, A., Palombi, F., Criscuolo, E., Frasca, F., Pierangeli, A., Mancini, N., Antonelli, G., Clementi, M., et al. 2021. Naringenin is a powerful inhibitor of SARS-CoV- 2 infection in vitro. Pharmacol. Res. 163, 105255.
David, A.B., Diamant, E., Dor, E., Barnea, A., Natan, N., Levin, L., Chapman, S., Mimran, L.C., Epstein, E., Zichel, R., et al. 2021. Identification of SARS-CoV-2 receptor binding inhibitors by in vitro screening of drug libraries. Molecules 26, 3213.
Du, R., Cooper, L., Chen, Z., Lee, H., Rong, L., and Cui, Q. 2021. Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CLpro. Antiviral Res. 190, 105075.
Fan, S., Zhen, Q., Chen, C., Wang, W., Wu, Q., Ma, H., Zhang, C., Zhang, L., Lu, B., Ge, H., et al. 2021. Clinical efficacy of low-dose emetine for patients with COVID-19: a real-world study. J. BioX Res. 4, 53–59.
Ghosh, S., Dellibovi-Ragheb, T.A., Kerviel, A., Pak, E., Qiu, Q., Fisher, M., Takvorian, P.M., Bleck, C., Hsu, V.W., Fehr, A.R., et al. 2020. β-Coronaviruses use lysosomes for egress instead of the biosynthetic secretory pathway. Cell 183, 1520–1535.
Goc, A., Sumera, W., Rath, M., and Niedzwiecki, A. 2021. Phenolic compounds disrupt spike-mediated receptor-binding and entry of SARS-CoV-2 pseudo-virions. PLoS ONE 16, e0253489.
Grose, M., Ruetalo, N., Layer, M., Hu, D., Businger, R., Rheber, S., Setz, C., Rauch, P., Auth, J., Froba, M., et al. 2021. Quinine inhibits infection of human cell lines with SARS-CoV-2. Viruses 13, 647.
He, C.L., Huang, L.Y., Wang, K., Gu, C.J., Hu, J., Zhang, G.J., Xu, W., Xie, Y.H., Tang, N., and Huang, A.L. 2021. Identification of bis-benzylisoquinoline alkaloids as SARS-CoV-2 entry inhibitors from a library of natural products. Sig. Transduct. Target. Ther. 6, 131.
Henss, L., Auste, A., Schurmann, C., Schmidt, C., von Rhein, C., Muhlebach, M.D., and Schnierle, B.S. 2021. The green tea catechin epigallocatechin gallate inhibits SARS-CoV-2 infection. J. Gen. Virol. 102, 001574.
Ho, J.S.Y., Mok, B.W.Y., Campisi, L., Jordan, T., Yildiz, S., Parameswaran, S., Wayman, J.A., Gaudreault, N.N., Meekins, D.A., Indran, S.V., et al. 2021. TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation. Cell 184, 2618–2632.
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Kruger, N., Herrler, T., Erichsen, S., Schiergens, T.S., Herrler, G., Wu, N.H., Nitsche, A., et al. 2020. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280.
Hong, S., Seo, S.H., Woo, S.J., Kwon, Y., Song, M., and Ha, N.C. 2021. Epigallocatechin gallate inhibits the uridylate-specific endoribonuclease Nsp15 and efficiently neutralizes the SARS-CoV-2 strain. J. Agric. Food Chem. 69, 5948–5954.
Huang, S., Liu, Y., Zhang, Y., Zhang, R., Zhu, C., Fan, L., Pei, G., Zhang, B., and Shi, Y. 2020. Baicalein inhibits SARS-CoV-2/VSV replication with interfering mitochondrial oxidative phosphorylation in a mPTP dependent manner. Sig. Transduct. Target. Ther. 5, 266.
Huang, L., Yuen, T.T.T., Ye, Z., Liu, S., Zhang, G., Chu, H., and Yue, J. 2021. Berbamine inhibits SARS-CoV-2 infection by compromising TRPMLs-mediated endolysosomal trafficking of ACE2. Sig. Transduct. Target. Ther. 6, 168.
Islam, M.T., Sarkar, C., El-Kersh, D.M., Jamaddar, S., Uddin, S.J., Shilpi, J.A., and Mubarak, M.S. 2020. Natural products and their derivatives against coronavirus: a review of the non-clinical and pre-clinical data. Phytother. Res. 34, 2471–2492.
Jan, J.T., Cheng, T.R., Juang, Y.P., Ma, H.H., Wu, Y.T., Yang, W.B., Cheng, C.W., Chen, X., Chou, T.H., Shie, J.J., et al. 2021. Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection. Proc. Natl. Acad. Sci. USA 118, e2021579118.
Jang, M., Park, Y.I., Cha, Y.E., Park, R., Namkoong, S., Lee, J.I., and Park, J. 2020. Tea polyphenols EGCG and theaflavin inhibit the activity of SARS-CoV-2 3CL-protease in vitro. Evid. Based Complement. Alternat. Med. 2020, 5630838.
Jo, S., Kim, S., Kim, D.Y., Kim, M.S., and Shin, D.H. 2020. Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro. J. Enzyme Inhib. Med. Chem. 35, 1539–1544.
Kanjanasirirat, P., Suksatu, A., Manopwisedjaroen, S., Munyoo, B., Tuchinda, P., Jearawuttanakul, K., Seemakhan, S., Charoensutthivarakul, S., Wongtrakoongate, P., Rangkasenee, N., et al. 2020. High-content screening of Thai medicinal plants reveals Boesenbergia rotunda extract and its component Panduratin A as anti-SARS-CoV-2 agents. Sci. Rep. 10, 19963.
Khan, A., Heng, W., Wang, Y., Qiu, J., Wei, X., Peng, S., Saleem, S., Khan, M., Ali, S.S., and Wei, D.Q. 2021. In silico and in vitro evaluation of kaempferol as a potential inhibitor of the SARSCoV- 2 main protease (3CLpro). Phytother. Res. 35, 2841–2845.
Kim, T.Y., Jeon, S., Jang, Y., Gotina, L., Won, J., Ju, Y.H., Kim, S., Jang, M.W., Won, W., Park, M.G., et al. 2021. Platycodin D, a natural component of Platycodon grandiflorum, prevents both lysosome- and TMPRSS2-driven SARS-CoV-2 infection by hindering membrane fusion. Exp. Mol. Med. 53, 956–972.
Ku, K.B., Shin, H.J., Kim, H.S., Kim, B.T., Kim, S.J., and Kim, C. 2020. Repurposing screens of FDA-approved drugs identify 29 inhibitors of SARS-CoV-2. J. Microbiol. Biotechnol. 30, 1843–1853.
Kumar, R., Afsar, M., Khandelwal, N., Chander, Y., Riyesh, T., Dedar, R.K., Gulati, B.R., Pal, Y., Barua, S., Tripathi, B.N., et al. 2021. Emetine suppresses SARS-CoV-2 replication by inhibiting interaction of viral mRNA with eIF4E. Antiviral Res. 189, 105056.
Kurek, J. 2019. Introductory Chapter: Alkaloids - Their Importance in Nature and for Human Life. IntechOpen, doi: https://doi.org/10.5772/intechopen.85400. Available from: https://www.intechopen.com/chapters/66742.
Lim, C.T., Tan, K.W., Wu, M., Ulferts, R., Armstrong, L.A., Ozono, E., Drury, L.S., Milligan, J.C., Zeisner, T.U., Zeng, J., et al. 2021. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp3 papain-like protease. Biochem. J. 478, 2517–2531.
Liu, P., Liu, H., Sun, Q., Liang, H., Li, C., Deng, X., Liu, Y., and Lai, L. 2020. Potent inhibitors of SARS-CoV-2 3C-like protease derived from N-substituted isatin compounds. Eur. J. Med. Chem. 206, 112702.
Liu, H., Ye, F., Sun, Q., Liang, H., Li, C., Li, S., Lu, R., Huang, B., Tan, W., and Lai, L. 2021. Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro. J. Enzyme Inhib. Med. Chem. 36, 497–503.
Nishimura, H., Okamoto, M., Dapat, I., Katumi, M., and Oshitani, H. 2021. Inactivation of SARS-CoV-2 by catechins from green tea. Jpn. J. Infect. Dis. 74, 421–423.
Ohashi, H., Watashi, K., Saso, W., Shionoya, K., Iwanami, S., Hirokawa, T., Shirai, T., Kanaya, S., Ito, Y., Kim, K.S., et al. 2021. Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment. iScience 24, 102367.
Ohgitani, E., Shin-Ya, M., Ichitani, M., Kobayashi, M., Takihara, T., Kawamoto, M., Kinugasa, H., and Mazda, O. 2021. Significant inactivation of SARS-CoV-2 In vitro by a green tea catechin, a catechin-derivative, and black tea galloylated theaflavins. Molecules 26, 3572.
Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., et al. 2020. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 11, 1620.
Pasquereau, S., Nehme, Z., Haidar Ahmad, S., Daouad, F., Van Assche, J., Wallet, C., Schwartz, C., Rohr, O., Morot-Bizot, S., and Herbein, G. 2021. Resveratrol inhibits HCoV-229E and SARSCoV-2 coronavirus replication in vitro. Viruses 13, 354.
Pawar, K.S., Mastud, R.N., Pawar, S.K., Pawar, S.S., Bhoite, R.R., Bhoite, R.R., Kulkarni, M.V., and Deshpande, A.R. 2021. Oral curcumin with piperine as adjuvant therapy for the treatment of COVID-19: a randomized clinical trial. Front. Pharmacol. 12, 669362.
Perveen, S. 2021. Introductory chapter: terpenes and terpenoids. IntechOpen, doi: https://doi.org/10.5772/intechopen.79683. Available from: https://www.intechopen.com/chapters/62573.
Pillon, M.C., Frazier, M.N., Dillard, L.B., Williams, J.G., Kocaman, S., Krahn, J.M., Perera, L., Hayne, C.K., Gordon, J., Stewart, Z.D., et al. 2021. Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight into nuclease specificity and dynamics. Nat. Commun. 12, 636.
Pitsillou, E., Liang, J., Karagiannis, C., Ververis, K., Darmawan, K.K., Ng, K., Hung, A., and Karagiannis, T.C. 2020a. Interaction of small molecules with the SARS-CoV-2 main protease in silico and in vitro validation of potential lead compounds using an enzyme-linked immunosorbent assay. Comput. Biol. Chem. 89, 107408.
Pitsillou, E., Liang, J., Ververis, K., Lim, K.W., Hung, A., and Karagiannis, T.C. 2020b. Identification of small molecule inhibitors of the deubiquitinating activity of the SARS-CoV-2 papain-like protease: in silico molecular docking studies and in vitro enzymatic activity assay. Front. Chem. 8, 623971.
Pizzorno, A., Padey, B., Dubois, J., Julien, T., Traversier, A., Dulière, V., Brun, P., Lina, B., Rosa-Calatrava, M., and Terrier, O. 2020. In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2. Antiviral Res. 181, 104878.
Rahman, H.S., Othman, H.H., Hammadi, N.I., Yeap, S.K., Amin, K.M., Abdul Samad, N., and Alitheen, N.B. 2020. Novel drug delivery systems for loading of natural plant extracts and their biomedical applications. Int. J. Nanomedicine 15, 2439–2483.
Salas Rojas, M., Silva Garcia, R., Bini, E., Pŕez De La Cruz, V., León Contreras, J.C., Hernández Pando, R., Bastida Gonzalez, F., Davila-Gonzalez, E., Orozco Morales, M., Gamboa Domínguez, A., et al. 2021. Quinacrine, an antimalarial drug with strong activity inhibiting SARS-CoV-2 viral replication in vitro. Viruses 13, 121.
Sa-Ngiamsuntorn, K., Suksatu, A., Pewkliang, Y., Thongsri, P., Kanjanasirirat, P., Manopwisedjaroen, S., Charoensutthivarakul, S., Wongtrakoongate, P., Pitiporn, S., Chaopreecha, J., et al. 2021. Anti-SARS-CoV-2 activity of Andrographis paniculata extract and its major component andrographolide in human lung epithelial cells and cytotoxicity evaluation in major organ cell representatives. J. Nat. Prod. 84, 1261–1270.
Santos, E.L., Sales Maia, B.H.L.N., Ferriani, A.P., and Teixeira, S.D. 2017. Flavonoids: classification, biosynthesis and chemical ecology. IntechOpen, DOI: https://doi.org/10.5772/67861. Available from: https://www.intechopen.com/chapters/54574.
Shi, T.H., Huang, Y.L., Chen, C.C., Pi, W.C., Hsu, Y.L., Lo, L.C., Chen, W.Y., Fu, S.L., and Lin, C.H. 2020. Andrographolide and its fluorescent derivative inhibit the main proteases of 2019-nCoV and SARS-CoV through covalent linkage. Biochem. Biophys. Res. Commun. 533, 467–473.
Song, J., Zhang, L., Xu, Y., Yang, D., Zhang, L., Yang, S., Zhang, W., Wang, J., Tian, S., Yang, S., et al. 2021. The comprehensive study on the therapeutic effects of baicalein for the treatment of COVID-19 in vivo and in vitro. Biochem. Pharmacol. 183, 114302.
Stefanik, M., Strakova, P., Haviernik, J., Miller, A.D., Ruzek, D., and Eyer, L. 2021. Antiviral activity of vacuolar ATPase blocker diphyllin against SARS-CoV-2. Microorganisms 9, 471.
Su, H.X., Yao, S., Zhao, W.F., Li, M.J., Liu, J., Shang, W.J., Xie, H., Ke, C.Q., Hu, H.C., Gao, M.N., et al. 2020. Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients. Acta Pharmacol. Sin. 41, 1167–1177.
ter Ellen, B.M., Dinesh Kumar, N., Bouma, E.M., Troost, B., Van De Pol, D.P.I., Van Der Ende-Metselaar, H.H., Apperloo, L., Van Gosliga, D., Van Den Berge, M., Nawijn, M.C., et al. 2021. Resveratrol and pterostilbene inhibit SARS-CoV-2 replication in air-liquid interface cultured human primary bronchial epithelial cells. Viruses 13, 1335.
The RECOVERY Collaborative Group. 2021. Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 384, 693–704.
Tito, A., Colantuono, A., Pirone, L., Pedone, E., Intartaglia, D., Giamundo, G., Conte, I., Vitaglione, P., and Apone, F. 2021. Pomegranate peel extract as an inhibitor of SARS-CoV-2 spike binding to human ACE2 receptor (in vitro): a promising source of novel antiviral drugs. Front. Chem. 9, 231.
Tompa, D.R., Immanuel, A., Srikanth, S., and Kadhirvel, S. 2021. Trends and strategies to combat viral infections: a review on FDA approved antiviral drugs. Int. J. Biol. Macromol. 172, 524–541.
V’kovski, P., Kratzel, A., Steiner, S., Stalder, H., and Thiel, V. 2021. Coronavirus biology and replication: implications for SARSCoV-2. Nat. Rev. Microbiol. 19, 155–170.
Valizadeh, H., Abdolmohammadi-Vahid, S., Danshina, S., Ziya Gencer, M., Ammari, A., Sadeghi, A., Roshangar, L., Aslani, S., Esmaeilzadeh, A., Ghaebi, M., et al. 2020. Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients. Int. Immunopharmacol. 89, 107088.
van de Sand, L., Bormann, M., Alt, M., Schipper, L., Heilingloh, C.S., Steinmann, E., Todt, D., Dittmer, U., Elsner, C., Witzke, O., et al. 2021. Glycyrrhizin effectively inhibits SARS-CoV-2 replication by inhibiting the viral main protease. Viruses 13, 609.
Varghese, F., Van Woudenbergh, E., Overheul, G., Eleveld, M., Kurver, L., Van Heerbeek, N., Van Laarhoven, A., Miesen, P., Den Hartog, G., De Jonge, M., et al. 2021. Berberine and obatoclax inhibit SARS-CoV-2 replication in primary human nasal epithelial cells in vitro. Viruses 13, 282.
Wang, S.C., Chen, Y., Wang, Y.C., Wang, W.J., Yang, C.S., Tsai, C.L., Hou, M.H., Chen, H.F., Shen, Y.C., and Hung, M.C. 2020a. Tannic acid suppresses SARS-CoV-2 as a dual inhibitor of the viral main protease and the cellular TMPRSS2 protease. Am. J. Cancer Res. 10, 4538–4546.
Wang, A., Sun, Y., Liu, Q., Wu, H., Liu, J., He, J., Yu, J., Chen, Q.Q., Ge, Y., Zhang, Z., et al. 2020b. Low dose of emetine as potential anti-SARS-CoV-2 virus therapy: preclinical in vitro inhibition and in vivo pharmacokinetic evidences. Mol. Biomed. 1, 14.
WHO, World Health Organization. 2020. WHO Coronavirus (COVID- 19) Dashboard. Available at: https://covid19.who.int.
Xia, B., Shen, X., He, Y., Pan, X., Liu, F.L., Wang, Y., Yang, F., Fang, S., Wu, Y., Duan, Z., et al. 2021. SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target. Cell Res. 31, 847–860.
Xu, J., Xu, Z., and Zheng, W. 2017. A review of the antiviral role of green tea catechins. Molecules 22, 1337.
Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., and Zhou, Q. 2020. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367, 1444–1448.
Yang, C.W., Lee, Y.Z., Hsu, H.Y., Jan, J.T., Lin, Y.L., Chang, S.Y., Peng, T.T., Yang, R.B., Liang, J.J., Liao, C.C., et al. 2020. Inhibition of SARS-CoV-2 by highly potent broad-spectrum anti-coronaviral tylophorine-based derivatives. Front. Pharmacol. 11, 606097.
Yang, M., Wei, J., Huang, T., Lei, L., Shen, C., Lai, J., Yang, M., Liu, L., Yang, Y., Liu, G., et al. 2021a. Resveratrol inhibits the replication of severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) in cultured Vero cells. Phytother. Res. 35, 1127–1129.
Yang, S., Xu, M., Lee, E.M., Gorshkov, K., Shiryaev, S.A., He, S., Sun, W., Cheng, Y.S., Hu, X., Tharappel, A.M., et al. 2018. Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry. Cell Discov. 4, 31.
Yang, Y., Yang, P., Huang, C., Wu, Y., Zhou, Z., Wang, X., and Wang, S. 2021b. Inhibitory effect on SARS-CoV-2 infection of neferine by blocking Ca2+-dependent membrane fusion. J. Med. Virol. 93, 5825–5832.
Zhan, Y., Ta, W., Tang, W., Hua, R., Wang, J., Wang, C., and Lu, W. 2021. Potential antiviral activity of isorhamnetin against SARSCoV- 2 spike pseudotyped virus in vitro. Drug Dev. Res. doi: https://doi.org/10.1002/ddr.21815.
Zhang, Y.N., Zhang, Q.Y., Li, X.D., Xiong, J., Xiao, S.Q., Wang, Z., Zhang, Z.R., Deng, C.L., Yang, X.L., Wei, H.P., et al. 2020. Gemcitabine, lycorine and oxysophoridine inhibit novel coronavirus (SARS-CoV-2) in cell culture. Emerg. Microbes Infect. 9, 1170–1173.
Zhao, Y., Du, X., Duan, Y., Pan, X., Sun, Y., You, T., Han, L., Jin, Z., Shang, W., Yu, J., et al. 2021. High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors. Protein Cell 1-12. doi:https://doi.org/10.1007/s13238-021-00836-9.
Acknowledgements
This work was supported by Korea University Grant (K211-2821). Figure 1 was adapted from the “Life Cycle of Coronavirus” from BioRender.com.
Author information
Authors and Affiliations
Corresponding author
Additional information
Conflict of Interest
The authors have no conflict of interest to disclose.
Rights and permissions
About this article
Cite this article
Españo, E., Kim, J., Lee, K. et al. Phytochemicals for the treatment of COVID-19. J Microbiol. 59, 959–977 (2021). https://doi.org/10.1007/s12275-021-1467-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12275-021-1467-z